Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-06-16
DOI
10.1093/neuonc/noaa145
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
- (2020) Albert Liclican et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Phase I study of tirabrutinib ( ONO ‐4059/ GS ‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
- (2019) Wataru Munakata et al. CANCER SCIENCE
- Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
- (2019) C. Soussain et al. EUROPEAN JOURNAL OF CANCER
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease
- (2018) Jacquelyn R. Bedsaul et al. Frontiers in Immunology
- Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL)
- (2017) Yasuji Miyakita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group
- (2017) B Kasenda et al. LEUKEMIA
- Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap
- (2017) Aparna Lakshmanan et al. Cancer Discovery
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
- (2017) Christian Grommes et al. Cancer Discovery
- Genomic characterization of primary central nervous system lymphoma
- (2016) Kazutaka Fukumura et al. ACTA NEUROPATHOLOGICA
- Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma
- (2016) Agnieszka Korfel et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
- (2016) Sophie Langner-Lemercier et al. NEURO-ONCOLOGY
- Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series
- (2016) Kamal Chamoun et al. NEUROLOGY
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
- (2015) H. S. Walter et al. BLOOD
- Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
- (2015) S. Bernard et al. BLOOD
- Recurrent mutations ofCD79BandMYD88are the hallmark of primary central nervous system lymphomas
- (2015) T. Nakamura et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Targets for Ibrutinib Beyond B Cell Malignancies
- (2015) A. Berglöf et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma
- (2011) M Deckert et al. LEUKEMIA
- Rituximab monotherapy for patients with recurrent primary CNS lymphoma
- (2011) T. T. Batchelor et al. NEUROLOGY
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
- (2008) Carole Soussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now